-Mar-20 31-Mar-20 31-Dec-18 Interest bearing debt to equity (time) 2.84 1.10 0.56 Net interest bearing debt to equity (time) 2.21 0.47 0.20 Debt to equity (time) 3.70 1.96 1.22 31-Mar-20 31-Mar-20 31-Dec
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
+ upload เอกสารประกอบ Filing (69-Debt-PO) มีผล 1,5,10 วันท าการ (แล้วแต่กรณี) ขาย รายงานการไถ่ถอน/ใช้สิทธิ รายงานผลการขาย Online พร้อม upload เอกสารประกอบ ไถ่ถอน/ใช้สิทธิ ภำยใน 15 วนันบัแต่สิน้เดือนที่เสนอ
from the heads quarter in approximately 265 Million Baht. There will no impact on shareholders’ benefits. If the Company drawdowns loan from financial institution, debt to equity ratio will be increased
BIBOR 3-month plus percent of fixed rate per annum 2.2.4 Long-term debt of FPT under rehabilitation plan with Bangchak Petroleum Plc. was of Bt10.5 million. 2.2.5 The Employee benefit obligations was of
. This came from increment of number of staff to support new incoming projects. 6.2 Provision for doubtful debt decreased in amount of Baht 7.17 million due to payment received from the debtors 6.3 Other
the subsidiary and payment of dividends to the Company’s shareholders and the non-controlling interests of the subsidiary. The appropriate of capital structure The Group’s debt to equity ratio as at 31
million mainly from the balance of US dollar debt and payables while THB and VND were appreciated against US dollar in this period; and • Non-operating expenses of Baht 135 million, primarily from 1) a non
Bt2.2 million at the rate of MLR minus percent of fixed rate per annum 2.2.4 Long-term debt of FPT under rehabilitation plan was of Bt3.8 million. 2.2.5 The Employee benefit obligations was of Bt1,134.9
transaction of purchasing FKRMM in Malaysia in 2019, so there is no remaining debt for this transaction. Please be informed accordingly, Yours faithfully, ............................................... (Mr